The Drug Enforcement Administration has issued a final rule that, effective May 8, places the synthetic opioid beta-hydroxythiofentanyl, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, into schedule I of the Controlled Substances Act.

This substance was previously placed into schedule I temporarily; as a result, this rule permanently continues the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (import, export, manufacture, distribute, engage in research, conduct instructional activities or chemical analysis, or possess) or proposed to handle this substance. These include the following.

- all importation and exportation of this substance must be in compliance with 21 USC 952, 953, 957, and 958 and in accordance with 21 CFR part 1312

- any activity involving this substance that is not authorized by, or is in violation of, the CSA or its implementing regulations is unlawful and may subject the person to administrative, civil, or criminal sanctions

- any person who handles or desires to handle this substance must be registered with the DEA to conduct such activities

- all labels and labeling for commercial containers of this substance must comply with 21 USC 825 and 958(e) and conform with 21 CFR part 1302

- only registered manufacturers are permitted to manufacture this substance in accordance with an assigned quota

- every DEA registrant that possesses any quantity of this substance must maintain an inventory of all stocks on hand as of May 8

Copyright © 2023 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.

ST&R: International Trade Law & Policy

Since 1977, we have set the standard for international trade lawyers and consultants, providing comprehensive and effective customs, import and export services to clients worldwide.

View Our Services 


Cookie Consent

We have updated our Privacy Policy relating to our use of cookies on our website and the sharing of information. By continuing to use our website or subscribe to our publications, you agree to the Privacy Policy and Terms & Conditions.